Serotonin mechanisms in heart valve disease II: The 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells

American Journal of Pathology

Volumn 161, Issue 6, 2002, Pages 2209-2218

  Xu, Jie ^a   Jian, Bo ^a   Chu, Richard ^b   Lu, Zhibin ^a   Li, Quanyi ^a   Dunlop, John ^c   Rosenzweig Lipson, Sharon ^c   McGonigle, Paul ^c   Levy, Robert J ^a   Liang, Bruce ^b,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOLIPASE C; PROTEIN KINASE C INHIBITOR; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; LEYDIG CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEEP; SIGNAL TRANSDUCTION; SWINE; VALVULAR HEART DISEASE;

EID: 0036899272     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64497-5     Document Type: Article

References (45)

1. Waltenberger J, Lundin L, Oberg K, Wilander E, Miyazono K, Heldin CH, Funa K: Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993, 142:71-78
2. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM: Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995, 92:790-795
3. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999, 340:858-868
4. Ferrans VJ, Roberts WC: The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol 1976, 7:387-409
5. Hafizi S, Taylor PM, Chester AH, Allen SP, Yacoub MH: Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. J Heart Valve Dis 2000, 9:454-458
6. Jian B, Xu J, Savani R, Narula N, Liang B, Levy R: Serotonin mechanisms in heart valve disease I. Serotonin induced upregulation of TGF-B1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002, 161:2207-2216
7. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57:75-81
8. Roy A, Brand NJ, Yacoub MH: Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000, 9:256-261
9. Greene EL, Houghton O, Collinsworth G, Garnovskaya MN, Nagai T, Saijad T, Bheemanathini V, Grewal JS, Paul RV, Raymond JR: 5-HT (2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells. Am J Physiol 2000, 278:F650-F658
10. Nebigil CG, Launay JM, Hickel P, Tournois C, Maroteaux L: 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: Crosstalk with tyrosine kinase pathways. Proc Natl Acad Sci USA 2000, 97:2591-2596
11. Rosel P, Arranz B, San L, Vallejo J, Crespo JM, Urretavizcaya M, Navarro MA: Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000, 99:173-181
12. Berridge MJ, Dawson RM, Downes CP, Heslop JP, Irvine RF: Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 1983, 212: 473-482
13. Svartengren J, Simonsson P: Receptor binding properties of amperozide. Pharmacol Toxicol 1990, 66(Suppl)1:S8-S11
14. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB: An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994, 216:276-284
15. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254
16. Baxter G, Kennett G, Blaney F, Blackburn T: 5-HT2 receptor subtypes: A family reunited? Trends Pharmacol Sci 1995, 16:105-110
17. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP: SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997, 36:609-620
18. Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP: In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 1996, 117:427-434
19. Kennett GA, Ainsworth K, Trail B, Blackburn TP: BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 1997, 36:233-239
20. Taylor SJ, Chae HZ, Rhee SG, Exton JH: Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 1991, 350:516-518
21. Roth BL, Willins DL, Kristiansen K, Kroeze WK: 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function. Pharmacol Ther 1998, 79:231-257
22. Jalili T, Takeishi Y, Walsh RA: Signal transduction during cardiac hypertrophy: The role of G alpha q, PLC beta I, and PKC. Cardiovasc Res 1999, 44:5-9
23. Lopez-Ilasaca M: Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 1998, 56:269-277
24. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ: Role of c-Src tyrosine kinase in G protein-coupled receptor-and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996, 271:19443-19450
25. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588
26. Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA: Surgical management of left-sided carcinoid heart disease. Circulation 2001, 104:136-140
27. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL: Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: Proliferative and fibrotic signals. Am J Physiol 1999, 276:F922-F930
28. Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, Matsuda H, Kobori S, Shichiri M: Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 1998, 54:1083-1092
29. Florian JA, Watts SW: Integration of mitogen-activated protein kinase kinase activation in vascular 5-hydroxytryptamine2A receptor signal transduction. J Pharmacol Exp Ther 1998, 284:346-355
30. Hahn A, Heusinger-Ribeiro J, Lanz T, Zenkel S, Goppelt-Struebe M: Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem 2000, 275:37429-37435
31. Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996, 8:402-411
32. Sugden PH, Clerk A: Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal 1997, 9:337-351
33. Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996, 8:205-215
34. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH: Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000, 275:37895-37901
35. Fringer J, Grinnell F: Fibroblast quiescence in floating or released collagen matrices: Contribution of the ERK signaling pathway and actin cytoskeletal organization. J Biol Chem 2001, 276:31047-31052
36. Goppelt-Struebe M, Hahn A, Stroebel M, Reiser CO: Independent regulation of cyclo-oxygenase 2 expression by p42/44 mitogen-activated protein kinases and Ca2+/calmodulin-dependent kinase. Biochem J 1999, 339:329-334
37. Chandler LJ, Sutton G, Dorairaj NR, Norwood D: N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures. J Biol Chem 2001, 276:2627-2636
38. Lee SL, Simon AR, Wang WW, Fanburg BL: H2O2 signals 5-HT induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol 2001, 281:L646-L652
39. Locher R, Brandes RP, Vetter W, Barton M: Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of Erk 1/2 mitogen-activated protein kinases. Hypertension 2002, 39:645-650
40. Jiang F, Jia Y, Cohen I: Fibronectin and protein kinases C-mediated activation of ERK/MAPK are essential for proplatelike formation. Blood 2002, 99:3579-3584
41. Gu J, Fujibayashi A, Yamada KM, Sekiguchi K: Laminin-10/11 and fibronectin differentially prevent apoptosis by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways. J Biol Chem 2002, 277:19922-19928
42. Cummins MM, Poronnik P, O'Mullane LM, Cook DI: Studying heterotrimeric G-protein-linked signal transduction using replication-deficient adenoviruses. Immunol Cell Biol 2000, 78:375-386
43. Vondriska TM, Zhang J, Song C, Tang XL, Cao X, Baines CP, Pass JM, Wang S, Bolli R, Ping P: Protein kinase C epsilon-Src modules direct signal transduction in nitric oxide-induced cardioprotection: Complex formation as a means for cardioprotective signaling. Circ Res 2001, 88:1306-1313
44. Akhand AA, Pu M, Senga T, Kato M, Suzuki H, Miyata T, Hamaguchi M, Nakashima I: Nitric oxide controls src kinase activity through a sulfhydryl group modification-mediated Tyr-527-independent and Tyr-416-linked mechanism. J Biol Chem 1999, 274:25821-25826
45. Gerhardt CC, van Heerikhuizen H: Functional characteristics of heterologously expressed 5-HT receptors. Eur J Pharmacol 1997, 334: 1-23